» Articles » PMID: 17868071

Synergistic Deposition of C4d by Complement-activating and Non-activating Antibodies in Cardiac Transplants

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2007 Sep 18
PMID 17868071
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

The role of non-complement-activating alloantibodies in humoral graft rejection is unclear. We hypothesized that the non-complement-activating alloantibodies synergistically activate complement in combination with complement-activating antibodies. B10.A hearts were transplanted into immunoglobulin knock out (Ig-KO) mice reconstituted with monoclonal antibodies to MHC class I antigens. In allografts of unreconstituted Ig-KO recipients, no C4d was detected. Similarly, reconstitution with IgG1 or low dose IgG2b alloantibodies did not induce C4d deposition. However, mice administered with a low dose of IgG2b combined with IgG1 had heavy linear deposits of C4d on vascular endothelium. C4d deposits correlated with decreased graft survival. To replicate this synergy in vitro, mononuclear cells from B10.A mice were incubated with antibodies to MHC class I antigens followed by incubation in normal mouse serum. Flow cytometry revealed that both IgG2a and IgG2b synergized with IgG1 to deposit C4d. This synergy was significantly decreased in mouse serum deficient in mannose binding lectin (MBL) and in serum deficient in C1q. Reconstitution of MBL-A/C knock out (MBL-KO) serum with C1q-knock out (C1q-KO) serum reestablished the synergistic activity. This suggests a novel role for non-complement-activating alloantibodies and MBL in humoral rejection.

Citing Articles

Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells.

Han J, Zimmerer J, Zeng Q, Chaudhari S, Satoskar A, Abdel-Rasoul M J Immunol. 2024; 212(9):1504-1518.

PMID: 38517294 PMC: 11047759. DOI: 10.4049/jimmunol.2300289.


CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.

Han J, Zimmerer J, Zeng Q, Chaudhari S, Hart M, Satoskar A Transplantation. 2023; 108(3):679-692.

PMID: 37872660 PMC: 10922067. DOI: 10.1097/TP.0000000000004828.


Animal Models for Heart Transplantation Focusing on the Pathological Conditions.

Tseng H, Lin Y, Huang C, Shih C, Tsai Y, Liu C Biomedicines. 2023; 11(5).

PMID: 37239085 PMC: 10216327. DOI: 10.3390/biomedicines11051414.


Molecular Signature of Antibody-Mediated Chronic Vasculopathy in Heart Allografts in a Novel Mouse Model.

Tsuda H, Dvorina N, Keslar K, Nevarez-Mejia J, Valenzuela N, Reed E Am J Pathol. 2022; 192(7):1053-1065.

PMID: 35490714 PMC: 9253905. DOI: 10.1016/j.ajpath.2022.04.003.


Antibody-suppressor CXCR5 CD8 T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice.

Zimmerer J, Han J, Peterson C, Zeng Q, Ringwald B, Cassol C Am J Transplant. 2022; 22(6):1550-1563.

PMID: 35114045 PMC: 9177711. DOI: 10.1111/ajt.16988.